BR9904283A - Complexos estáveis de compostos fracamente solúveis - Google Patents
Complexos estáveis de compostos fracamente solúveisInfo
- Publication number
- BR9904283A BR9904283A BR9904283-5A BR9904283A BR9904283A BR 9904283 A BR9904283 A BR 9904283A BR 9904283 A BR9904283 A BR 9904283A BR 9904283 A BR9904283 A BR 9904283A
- Authority
- BR
- Brazil
- Prior art keywords
- soluble compounds
- poorly soluble
- complexes
- ionic polymers
- insoluble
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 229920000831 ionic polymer Polymers 0.000 abstract 3
- 230000009477 glass transition Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10133698P | 1998-09-22 | 1998-09-22 | |
| US13653199P | 1999-05-28 | 1999-05-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9904283A true BR9904283A (pt) | 2000-09-26 |
Family
ID=26798138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9904283-5A BR9904283A (pt) | 1998-09-22 | 1999-09-21 | Complexos estáveis de compostos fracamente solúveis |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US6350786B1 (OSRAM) |
| EP (1) | EP0988863B2 (OSRAM) |
| JP (5) | JP2000095708A (OSRAM) |
| KR (1) | KR100362019B1 (OSRAM) |
| CN (1) | CN1201821C (OSRAM) |
| AR (2) | AR022096A1 (OSRAM) |
| AT (1) | ATE265232T1 (OSRAM) |
| AU (1) | AU770745B2 (OSRAM) |
| BR (1) | BR9904283A (OSRAM) |
| CA (1) | CA2282906C (OSRAM) |
| CO (1) | CO5140077A1 (OSRAM) |
| CZ (1) | CZ300215B6 (OSRAM) |
| DE (1) | DE69916733T3 (OSRAM) |
| DK (1) | DK0988863T4 (OSRAM) |
| ES (1) | ES2218918T5 (OSRAM) |
| HR (1) | HRP990287B1 (OSRAM) |
| HU (1) | HU228341B1 (OSRAM) |
| ID (1) | ID24034A (OSRAM) |
| IL (1) | IL131957A (OSRAM) |
| MA (1) | MA26692A1 (OSRAM) |
| MY (1) | MY124377A (OSRAM) |
| NO (1) | NO326928B1 (OSRAM) |
| NZ (1) | NZ337884A (OSRAM) |
| PE (1) | PE20001049A1 (OSRAM) |
| PL (1) | PL202757B1 (OSRAM) |
| PT (1) | PT988863E (OSRAM) |
| RS (1) | RS50193B (OSRAM) |
| RU (1) | RU2240827C2 (OSRAM) |
| SG (1) | SG97131A1 (OSRAM) |
| SI (1) | SI0988863T2 (OSRAM) |
| TR (1) | TR199902324A3 (OSRAM) |
| TW (1) | TWI234465B (OSRAM) |
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE400252T1 (de) | 1999-02-10 | 2008-07-15 | Pfizer Prod Inc | Pharmazeutische feste dispersionen |
| US6440959B1 (en) * | 1999-04-21 | 2002-08-27 | Hoffman-La Roche Inc. | Pyrazolobenzodiazepines |
| AR033651A1 (es) * | 1999-10-01 | 2004-01-07 | Hoffmann La Roche | Derivados de pirimidina-2,4,6-triona, composiciones farmaceuticas que contienen dichos compuestos y el empleo de los mismos para la manufactura de un medicamento |
| US6313143B1 (en) * | 1999-12-16 | 2001-11-06 | Hoffmann-La Roche Inc. | Substituted pyrroles |
| AU2001255438B2 (en) * | 2000-05-16 | 2005-03-24 | Ortho-Mcneil Pharmaceutical, Inc. | Process for coating medical devices using super-critical carbon dioxide |
| US6469179B1 (en) | 2000-10-03 | 2002-10-22 | Hoffmann-La Roche Inc. | Amorphous form of cell cycle inhibitor having improved solubility and bioavailability |
| US6482847B2 (en) | 2000-10-03 | 2002-11-19 | Hoffmann-La Roche Inc. | Amorphous form of cell cycle inhibitor having improved solubility and bioavailability |
| US7193084B2 (en) | 2000-12-22 | 2007-03-20 | Baxter International Inc. | Polymorphic form of itraconazole |
| US20050048126A1 (en) | 2000-12-22 | 2005-03-03 | Barrett Rabinow | Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug |
| US6607784B2 (en) | 2000-12-22 | 2003-08-19 | Baxter International Inc. | Microprecipitation method for preparing submicron suspensions |
| US9700866B2 (en) | 2000-12-22 | 2017-07-11 | Baxter International Inc. | Surfactant systems for delivery of organic compounds |
| US8067032B2 (en) | 2000-12-22 | 2011-11-29 | Baxter International Inc. | Method for preparing submicron particles of antineoplastic agents |
| US6951656B2 (en) | 2000-12-22 | 2005-10-04 | Baxter International Inc. | Microprecipitation method for preparing submicron suspensions |
| US6884436B2 (en) | 2000-12-22 | 2005-04-26 | Baxter International Inc. | Method for preparing submicron particle suspensions |
| US6977085B2 (en) | 2000-12-22 | 2005-12-20 | Baxter International Inc. | Method for preparing submicron suspensions with polymorph control |
| US6548531B2 (en) | 2001-02-09 | 2003-04-15 | Hoffmann-La Roche Inc. | Method for cancer therapy |
| US6716845B2 (en) * | 2001-03-30 | 2004-04-06 | Hoffmann-La Roche Inc. | Barbituric acid derivatives |
| ES2305250T3 (es) * | 2001-05-30 | 2008-11-01 | Csir | Procedimiento de encapsulacion de una sustancia activa. |
| US20030044514A1 (en) * | 2001-06-13 | 2003-03-06 | Richard Robert E. | Using supercritical fluids to infuse therapeutic on a medical device |
| WO2002102373A1 (en) * | 2001-06-15 | 2002-12-27 | F. Hoffmann-La Roche Ag | Method for administration of cancer therapeutic |
| WO2003000292A1 (en) | 2001-06-22 | 2003-01-03 | Pfizer Products Inc. | Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers |
| BR0210518A (pt) | 2001-06-22 | 2004-06-22 | Pfizer Prod Inc | Composições farmacêuticas de dispersões de drogas e polìmeros neutros |
| US20060003012A9 (en) | 2001-09-26 | 2006-01-05 | Sean Brynjelsen | Preparation of submicron solid particle suspensions by sonication of multiphase systems |
| CA2461349C (en) | 2001-09-26 | 2011-11-29 | Baxter International Inc. | Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal |
| US7112340B2 (en) | 2001-10-19 | 2006-09-26 | Baxter International Inc. | Compositions of and method for preparing stable particles in a frozen aqueous matrix |
| US20030139373A1 (en) * | 2001-11-20 | 2003-07-24 | Breimer Lars Holger | Method for cancer therapy |
| PT1469833T (pt) * | 2002-02-01 | 2021-07-13 | Bend Res Inc | Método para produzir dispersões de fármaco amorfo sólido seco por pulverização homogéneas utilizando aparelho de secagem por pulverização modificado |
| CN1681479A (zh) | 2002-08-12 | 2005-10-12 | 辉瑞产品公司 | 半有序药物和聚合物的药物组合物 |
| DE10351087A1 (de) * | 2003-10-31 | 2005-05-25 | Bayer Technology Services Gmbh | Feste Wirkstoff-Formulierung |
| WO2005046697A1 (ja) * | 2003-11-14 | 2005-05-26 | Ajinomoto Co., Inc. | フェニルアラニン誘導体の徐放性経口投与製剤 |
| KR101118930B1 (ko) * | 2003-11-14 | 2012-03-14 | 아지노모토 가부시키가이샤 | 페닐알라닌 유도체의 고체 분산체 또는 고체 분산체 의약제제 |
| JP4787240B2 (ja) * | 2004-04-01 | 2011-10-05 | ユニベルシテ・ド・リエージュ | ピリミジン−２，４，６−トリオンのシクロデキストリン包接複合体 |
| AR049915A1 (es) * | 2004-06-14 | 2006-09-13 | Anacor Pharmaceuticals Inc | Compuestos con contenido de boro y metodos de uso de los mismos |
| WO2006062980A2 (en) * | 2004-12-07 | 2006-06-15 | Nektar Therapeutics | Stable non-crystalline formulation comprising tiagabine |
| EP1839650A1 (en) * | 2004-12-28 | 2007-10-03 | Eisai R&D Management Co., Ltd. | Quick disintegration tablet and method of producing the same |
| CA2605214C (en) | 2004-12-31 | 2016-07-12 | Reddy Us Therapeutics, Inc. | Benzylamine derivatives as cetp inhibitors |
| US8604055B2 (en) | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
| EP1843798A2 (en) * | 2005-01-27 | 2007-10-17 | Corium International Inc., | Hydrophylic biocompatible adhesive formulations and uses |
| EP1690528A1 (de) * | 2005-02-11 | 2006-08-16 | Abbott GmbH & Co. KG | Herstellung von Dosierungsformen mit einer festen Dispersion eines mikrokristallinen Wirkstoffs |
| US20080274192A1 (en) * | 2005-05-19 | 2008-11-06 | Pfizer Inc. | Pharmaceutical Compositions Comprising an Amorphous Form of a Vegf-R-Inhibitor |
| EP1767194A1 (de) * | 2005-06-09 | 2007-03-28 | Helm AG | Verfahren zur Herstellung von Adsorbaten des Drospirenons |
| PT1893612E (pt) * | 2005-06-22 | 2011-11-21 | Plexxikon Inc | Derivados de pirrolo [2,3-b]piridina como inibidores de proteína quinase |
| US20080031944A1 (en) * | 2006-08-04 | 2008-02-07 | Cima Labs Inc. | Stabilization of lorazepam |
| CL2007002331A1 (es) * | 2006-08-10 | 2008-04-18 | Cipla Ltd | Composicion oral solida que comprede uno o mas farmacos antirretrovirales y al menos un polimero insoluble en agua, en relacion aproximadamente 1:1 hasta 1:6; proceso de elaboracion; y uso para el tratamiento del vih. |
| US20080107725A1 (en) * | 2006-10-13 | 2008-05-08 | Albano Antonio A | Pharmaceutical Solid Dosage Forms Comprising Amorphous Compounds Micro-Embedded in Ionic Water-Insoluble Polymers |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| WO2008079909A1 (en) * | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
| PE20121126A1 (es) * | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
| WO2008081829A1 (ja) | 2006-12-27 | 2008-07-10 | Astellas Pharma Inc. | 難水溶性薬物の溶解性維持用アミノアルキルメタアクリレートコポリマーｅ |
| JP2010526848A (ja) * | 2007-05-11 | 2010-08-05 | エフ．ホフマン−ラ ロシュ アーゲー | 難溶性薬物用の医薬組成物 |
| US8426467B2 (en) | 2007-05-22 | 2013-04-23 | Baxter International Inc. | Colored esmolol concentrate |
| US8722736B2 (en) | 2007-05-22 | 2014-05-13 | Baxter International Inc. | Multi-dose concentrate esmolol with benzyl alcohol |
| EP1997479A1 (en) * | 2007-05-31 | 2008-12-03 | Helm AG | Stabilized amorphous candesartan cilexetil compositions for oral administration |
| AU2008276063B2 (en) | 2007-07-17 | 2013-11-28 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| CN101896161A (zh) * | 2007-10-19 | 2010-11-24 | 普渡（大学）研究基金 | 结晶化合物的固体制剂 |
| US8632805B2 (en) * | 2008-06-20 | 2014-01-21 | Mutual Pharmaceutical Company, Inc. | Controlled-release formulations, method of manufacture, and use thereof |
| US7794750B2 (en) * | 2008-06-20 | 2010-09-14 | Mutual Pharmaceutical Company, Inc. | Controlled-release formulations, method of manufacture, and use thereof |
| US20100099696A1 (en) * | 2008-10-16 | 2010-04-22 | Anthony Edward Soscia | Tamper resistant oral dosage forms containing an embolizing agent |
| KR20100073454A (ko) * | 2008-12-23 | 2010-07-01 | 국립암센터 | 트란스글루타미나제 억제제로 사용되는 신규한 피라졸로디아제핀계 화합물, 이의 제조방법 및 이를 포함하는 조성물 |
| JP5511942B2 (ja) * | 2009-04-03 | 2014-06-04 | エフ ホフマン−ラ ロッシュ アクチェン ゲゼルシャフト | 組成物及びその使用 |
| US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
| EP2496086B1 (en) | 2009-11-06 | 2017-05-31 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| EP2581084A4 (en) * | 2010-05-31 | 2014-06-25 | Astellas Pharma Inc | SOLID DISPERSION COMPRISING A TRIAZOLE COMPOUND |
| SI2672967T1 (sl) | 2011-02-07 | 2018-12-31 | Plexxikon Inc. | Spojine in postopki za kinazno modulacijo in indikacije zanjo |
| BR112013021030A2 (pt) | 2011-02-17 | 2016-10-11 | Hoffmann La Roche | processo para cristalização controlada de um ingrediente farmacêutico ativo a partir de estado líquido super-refrigerado por extrusão por fusão a quente |
| AR085279A1 (es) | 2011-02-21 | 2013-09-18 | Plexxikon Inc | Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico |
| AP3310A (en) | 2011-06-20 | 2015-06-30 | Lundbeck & Co As H | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia |
| JP5964965B2 (ja) | 2011-08-18 | 2016-08-03 | ドクター レディズ ラボラトリーズ リミテッド | コレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての置換複素環式アミン化合物 |
| WO2013037396A1 (en) * | 2011-09-12 | 2013-03-21 | Bioneer A/S | Solution of polymer in api for a solid dosage form |
| AU2012313971B2 (en) | 2011-09-27 | 2016-09-29 | Dr. Reddy's Laboratories, Ltd. | 5 - benzylaminomethyl - 6 - aminopyrazolo [3, 4 -b] pyridine derivatives as cholesteryl ester -transfer protein (CETP) inhibitors useful for the treatment of atherosclerosis |
| EP2765990B1 (en) | 2011-10-14 | 2017-09-06 | Array Biopharma, Inc. | Solid dispersion |
| RU2018138976A (ru) * | 2012-03-23 | 2018-12-06 | Эррэй Биофарма Инк. | Лечение рака головного мозга |
| US20140128431A1 (en) | 2012-04-03 | 2014-05-08 | Hoffmann-Laroche Inc. | Pharmaceutical composition with improved bioavailability, safety and tolerability |
| EP2649989B1 (en) | 2012-04-13 | 2017-10-18 | King Saud University | Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof |
| US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| JO3339B1 (ar) * | 2012-09-11 | 2019-03-13 | Shanghai Inst Pharmaceutical Ind | شكل مستقر غير متبلور من الأغوميلاتين وعملية تحضيره والتركيبات الدوائية التي تحتوي عليه |
| US20170071930A1 (en) | 2012-11-19 | 2017-03-16 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical compositions of cetp inhibitors |
| EP2934486A2 (en) * | 2012-12-20 | 2015-10-28 | Kashiv Pharma, LLC | Orally disintegrating tablet formulation for enhanced bioavailability |
| KR101737250B1 (ko) | 2013-01-22 | 2017-05-17 | 에프. 호프만-라 로슈 아게 | 개선된 생체이용률을 갖는 약학 조성물 |
| TWI615157B (zh) | 2013-02-06 | 2018-02-21 | 大塚製藥股份有限公司 | 包括不定形西洛他唑的固體分散劑 |
| WO2015038376A1 (en) * | 2013-09-11 | 2015-03-19 | 3M Innovative Properties Company | Coating compositions, dental structures thereof and methods for generating contrast |
| EP3076951B1 (en) * | 2013-12-05 | 2020-09-30 | Celal Albayrak | Process for the production of drug formulations for oral administration |
| PT107846B (pt) * | 2014-08-01 | 2019-03-22 | Hovione Farm S A | Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada |
| RU2017144222A (ru) * | 2015-05-29 | 2019-07-02 | Сан Фармасьютикал Индастриз Лимитед | Фармацевтическая пероральная композиция изотретиноина |
| SMT202500245T1 (it) | 2016-12-13 | 2025-07-22 | Transthera Sciences Nanjing Inc | Composto inibitore multi-chinasi, forma cristallina e suo utilizzo |
| CA3060407A1 (en) | 2017-04-28 | 2018-11-01 | Seattle Genetics, Inc. | Treatment of her2 positive cancers |
| KR102082775B1 (ko) * | 2017-05-02 | 2020-02-28 | 주식회사 삼양바이오팜 | 수용해도 및 생체이용율이 개선된 조성물 |
| RU2725879C2 (ru) * | 2018-07-26 | 2020-07-07 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Казанский Государственный медицинский университет" Министерства здравоохранения Российской Федерации | Интерполимерный носитель для пероральных систем контролируемой доставки активных фармацевтических ингредиентов |
| US11535600B2 (en) | 2018-12-03 | 2022-12-27 | H. Lundbeck A/S | Prodrugs of 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine |
| IL294928A (en) * | 2020-01-24 | 2022-09-01 | Nanocopoeia Llc | Amorphous solid dispersions of dasatinib and uses thereof |
| AU2021212258A1 (en) | 2020-01-31 | 2022-09-29 | Flex Pharma, Llc | Amorphous nilotinib microparticles and uses thereof |
| JP7705715B2 (ja) | 2020-03-03 | 2025-07-10 | デクセリアルズ株式会社 | 画像表示装置の製造方法 |
| EP4142699A1 (en) | 2020-04-30 | 2023-03-08 | Nanocopoeia LLC | Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib |
| US11980619B2 (en) | 2021-07-28 | 2024-05-14 | Nanocopoeia, Llc | Pharmaceutical compositions and crushable tablets including amorphous solid dispersions of dasatinib and uses |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS51118816A (en) * | 1975-04-08 | 1976-10-19 | Meiji Seika Kaisha Ltd | A process for stabilizing non-crystalloidal solid |
| US4344934A (en) * | 1978-11-20 | 1982-08-17 | American Home Products Corporation | Therapeutic compositions with enhanced bioavailability |
| PT83812B (en) * | 1985-11-27 | 1988-03-15 | Syntex Inc | Process for preparing amorphous benzimidazole derivatives |
| GB8608080D0 (en) * | 1986-04-02 | 1986-05-08 | Fujisawa Pharmaceutical Co | Solid dispersion composition |
| NZ227850A (en) † | 1988-02-10 | 1991-11-26 | Hoffmann La Roche | Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders |
| JP2528706B2 (ja) † | 1988-05-30 | 1996-08-28 | ゼリア新薬工業株式会社 | ジヒドロピリジン化合物の製剤組成物 |
| USRE36736E (en) | 1989-02-06 | 2000-06-13 | Hoffman-La Roche Inc. | Substituted pyrroles |
| JPH0729926B2 (ja) † | 1989-07-25 | 1995-04-05 | 大塚製薬株式会社 | 易吸収性製剤用組成物 |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| ATE159426T1 (de) † | 1991-04-16 | 1997-11-15 | Nippon Shinyaku Co Ltd | Verfahren zur herstellung einer festen dispersion |
| US5281420A (en) | 1992-05-19 | 1994-01-25 | The Procter & Gamble Company | Solid dispersion compositions of tebufelone |
| TW493991B (en) | 1995-05-08 | 2002-07-11 | Novartis Ag | Pharmaceutical composition for oral administration of active agent having low water solubility and process for preparation of the same |
| GB9511220D0 (en) † | 1995-06-02 | 1995-07-26 | Glaxo Group Ltd | Solid dispersions |
| BE1009856A5 (fr) * | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
| WO1997004782A1 (en) * | 1995-07-26 | 1997-02-13 | Kyowa Hakko Kogyo Co., Ltd. | Solid dispersion or solid dispersion preparation of xanthine derivatives |
| WO1997008950A1 (en) † | 1995-09-07 | 1997-03-13 | Fuisz Technologies, Ltd. | System for rendering substantially non-dissoluble bio-affecting agents bio-available |
| DE19548624A1 (de) | 1995-12-23 | 1997-06-26 | Boehringer Mannheim Gmbh | Neue Barbitursäure-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| JPH09208459A (ja) * | 1996-02-07 | 1997-08-12 | Eisai Co Ltd | 溶解性を改良した製剤 |
| JP3737518B2 (ja) | 1996-03-12 | 2006-01-18 | ピージー−ティーエックスエル カンパニー， エル．ピー． | 水溶性パクリタキセルプロドラッグ |
| EP0954288B1 (en) * | 1996-06-28 | 2004-08-11 | Schering Corporation | Solid solution of an antifungal agent with enhanced bioavailability |
| PE91598A1 (es) | 1996-07-29 | 1998-12-24 | Hoffmann La Roche | Pirroles sustituidos |
| US6229011B1 (en) | 1997-08-22 | 2001-05-08 | Hoffman-La Roche Inc. | N-aroylphenylalanine derivative VCAM-1 inhibitors |
| CA2322689C (en) | 1998-03-17 | 2008-11-25 | F. Hoffmann-La Roche Ag | Substituted bisindolymaleimides for the inhibition of cell proliferation |
-
1999
- 1999-09-07 US US09/391,060 patent/US6350786B1/en not_active Expired - Lifetime
- 1999-09-13 SI SI9930573T patent/SI0988863T2/sl unknown
- 1999-09-13 DE DE69916733T patent/DE69916733T3/de not_active Expired - Lifetime
- 1999-09-13 EP EP99117908A patent/EP0988863B2/en not_active Expired - Lifetime
- 1999-09-13 DK DK99117908T patent/DK0988863T4/da active
- 1999-09-13 AT AT99117908T patent/ATE265232T1/de active
- 1999-09-13 PT PT99117908T patent/PT988863E/pt unknown
- 1999-09-13 ES ES99117908T patent/ES2218918T5/es not_active Expired - Lifetime
- 1999-09-16 IL IL13195799A patent/IL131957A/xx not_active IP Right Cessation
- 1999-09-17 PE PE1999000947A patent/PE20001049A1/es not_active IP Right Cessation
- 1999-09-17 SG SG9904570A patent/SG97131A1/en unknown
- 1999-09-17 CO CO99059117A patent/CO5140077A1/es unknown
- 1999-09-17 NZ NZ337884A patent/NZ337884A/xx not_active IP Right Cessation
- 1999-09-17 CZ CZ0330499A patent/CZ300215B6/cs not_active IP Right Cessation
- 1999-09-20 CA CA2282906A patent/CA2282906C/en not_active Expired - Lifetime
- 1999-09-20 HU HU9903189A patent/HU228341B1/hu unknown
- 1999-09-20 TW TW088116184A patent/TWI234465B/zh not_active IP Right Cessation
- 1999-09-20 AR ARP990104725A patent/AR022096A1/es not_active Application Discontinuation
- 1999-09-20 AU AU48807/99A patent/AU770745B2/en not_active Expired
- 1999-09-20 ID IDP990878D patent/ID24034A/id unknown
- 1999-09-20 HR HR990287 patent/HRP990287B1/xx not_active IP Right Cessation
- 1999-09-20 MY MYPI99004065A patent/MY124377A/en unknown
- 1999-09-21 MA MA25778A patent/MA26692A1/fr unknown
- 1999-09-21 BR BR9904283-5A patent/BR9904283A/pt not_active Application Discontinuation
- 1999-09-21 NO NO19994583A patent/NO326928B1/no not_active IP Right Cessation
- 1999-09-21 RU RU99120377/15A patent/RU2240827C2/ru active
- 1999-09-21 CN CNB991194063A patent/CN1201821C/zh not_active Expired - Lifetime
- 1999-09-21 RS YUP-473/99A patent/RS50193B/sr unknown
- 1999-09-21 JP JP11267142A patent/JP2000095708A/ja not_active Withdrawn
- 1999-09-21 TR TR1999/02324A patent/TR199902324A3/tr unknown
- 1999-09-22 PL PL335592A patent/PL202757B1/pl unknown
- 1999-09-22 KR KR1019990041130A patent/KR100362019B1/ko not_active Expired - Lifetime
-
2007
- 2007-06-06 JP JP2007150911A patent/JP2007224048A/ja active Pending
-
2011
- 2011-04-13 AR ARP110101253A patent/AR080892A2/es not_active Application Discontinuation
-
2012
- 2012-10-18 JP JP2012230446A patent/JP6253135B2/ja not_active Expired - Lifetime
-
2015
- 2015-07-16 JP JP2015141952A patent/JP2015187170A/ja active Pending
-
2016
- 2016-08-31 JP JP2016169245A patent/JP6534979B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9904283A (pt) | Complexos estáveis de compostos fracamente solúveis | |
| BR9815159A (pt) | Preparação de conjugados de polietileno glicol-grf especìfica ao sìtio | |
| BR0110914A (pt) | Composição farmacêutica lìquida, conjugado, processo para preparação e utilização de uma composição, processo para o tratamento e prevenção de enfermidades que envolvem anemia e dispositivo para liberação local e sistêmica sustentada de uma composicão | |
| BR0210530A (pt) | Composições farmacêuticas de drogas e poìimeros acìdicos neutralizados | |
| BR0007742A (pt) | Conjugados iÈnicos moleculares de poliésteres biodegradáveis e polipeptìdeos bioativos | |
| CY1105953T1 (el) | Συνθεσεις για απελευθερωση συνδυασμων φαρμακων | |
| BR9911077A (pt) | Polìmeros absorventes de água com moléculas de espaço oco supramoleculares, processos para a sua preparação e seu emprego | |
| BR0014271A (pt) | Composições antivirais | |
| TR199900674T2 (xx) | Kinazolin t�revleri ve bunlar� i�eren farmas�tik bile�imler. | |
| DK1066044T3 (da) | Dextranformuleringer til behandling af inflammatoriske ledsygdomme | |
| FI924969A0 (fi) | Latenta kedoeverfoeringsmedel av tiolmerkaptantyp och deras anvaendning vid syntes av polymerer | |
| ATE312076T1 (de) | Thiol-modifizierte hyaluronan-derivate | |
| BR0000003A (pt) | Azalidas e métodos de preparação das mesmas | |
| AR008378A1 (es) | Conjudados de interferon | |
| ATE195721T1 (de) | Lipopolyamine als transfectionsmittel und ihre pharmazeutischen anwendungen | |
| ES2164218T3 (es) | Derivados de camptotecina. | |
| BR0112160A (pt) | Agentes antiinflamatórios seletivos para glicocorticóides | |
| BR0209020A (pt) | Composição farmacêutica de polialilamina | |
| MA20670A1 (fr) | Compositions par la preparation par extrusion de microparticules permettant la liberation prolongee d'une substance biologiquement active et les microparticules ainsi obtenues | |
| IT1282686B1 (it) | Composti in grado di ridurre la tossicita' da farmaci | |
| BR9901782A (pt) | Forma para dosagem de nefazodona. | |
| TR199802344A2 (xx) | �kame edilmi� imidazolidin t�revleri | |
| BR0011831A (pt) | Compostos, processo para preparar os mesmos, composições farmacêuticas, e, uso dos compostos | |
| DE602004019405D1 (de) | Pharmazeutische zubereitungen | |
| EP1229025A4 (en) | NEW QUINAZOLINE DERIVATIVES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08H | Application fees: decision cancelled [chapter 8.8 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1914 DE 11/09/2007 POR TER SIDO INDEVIDO. |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: ALTERADA DE INT.CL A61K47/48, A61K 47/32, A61K 47/38, A61K 31/18, A61K 31/216, A61K 31/404, A61K 31/515, A61K 31/5517, C07D 239/60, C07D 403/14, C07D 243/06 Ipc: A61K 47/48 (2008.04), A61K 47/32 (2008.04), A61K 4 |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE NAO ATENDE AO REQUISITO DE ATIVIDADE INVENTIVA ( ART. 8O E ART. 13 DA LPI ) |
|
| B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Ipc: A61K 9/14 (2006.01), A61K 47/56 (2017.0 |